Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery
-Company closes approximately $5.47 million in equity financing in 2Q/3Q25-TH104 potentially fills a critical National Security Need against Weaponized Fentanyl–TH023 may fulfill the promise of delivering a safe and effective oral antibody medication against inflammation-Company Strengthens Operational Leadership, Corporate Governance and Accounting RED BANK, NJ / ACCESS Newswire / August 4, 2025 / Tharimmune, Inc. […]